Tissue Regenix Group PLC DermaPure secures GPO agreement with Premier, Inc. (0223R)
December 06 2016 - 1:00AM
UK Regulatory
TIDMTRX
RNS Number : 0223R
Tissue Regenix Group PLC
06 December 2016
Tissue Regenix Group plc
DermaPure secures GPO agreement with Premier, Inc.
Leeds, 06 December 2016 - Tissue Regenix Group (AIM:TRX)
("Tissue Regenix" or "The Group") the regenerative medical devices
company today announces Tissue Regenix Wound Care, Inc. has secured
a Group Purchasing Organisation (GPO) contract with Premier Inc., a
leading healthcare improvement company.
DermaPure has been awarded this contract under a 'Breakthrough
Technology Agreement', which is awarded by the GPO after a thorough
four step review process is completed and it is determined that the
technology offers unique attributes to the other available
treatment options.
The Premier alliance is comprised of approximately 3,600 U.S.
based hospitals and 120,000 other healthcare providers which will
now have contracted access to DermaPure(R).
Antony Odell, CEO, Tissue Regenix Group plc commented: "Approval
under Premier's Breakthrough Technology Agreement marks a
significant milestone for DermaPure(R). This confirms the unique
characteristics of our patented dCELL(R) Technology, the powerful
clinical evidence we have collected, and the remarkable outcomes it
achieves in real world clinical situations."
For more Information:
Tissue Regenix Group plc Tel: 0330
Caitlin Pearson Corporate Communications 430 3073
Officer
========================================== ===========
Jefferies International Ltd Tel: 020
Simon Hardy / Harry Nicholas 7029 8000
========================================== ===========
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. The company's patented decellularisation
('dCELL(R)') technology removes DNA and other cellular material
from animal and human tissue leaving an acellular tissue scaffold
which is not rejected by the patient's body which can then be used
to repair diseased or worn out body parts. The potential
applications of this process are diverse and address many critical
clinical needs such as vascular disease, heart valve replacement
and knee repair.
Tissue Regenix was formed in 2006 when it was spun-out from the
University of Leeds. The company commercialises academic research
conducted by our partners around the World.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.', as
part of its commercialisation strategy for its dCELL(R) technology
platform.
This information is provided by RNS
The company news service from the London Stock Exchange
END
CNTTABLTMBAMBLF
(END) Dow Jones Newswires
December 06, 2016 02:00 ET (07:00 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Apr 2024 to May 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2023 to May 2024